pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer

Jemal, 2011, Global cancer statistics, CA Cancer J. Clin., 61, 69, 10.3322/caac.20107 Spiro, 2007, Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition), Chest, 132, 149S, 10.1378/chest.07-1358 Kroeber, 2014, A prospective phase I/II study: combination chemotherapy with docetaxel and pemetrexed as second-line treatment in patients with stage IIIB/IV non-small cell lung cancer, Case Rep. Oncol., 7, 435, 10.1159/000365323 Clegg, 2002, Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review, Thorax, 57, 20, 10.1136/thorax.57.1.20 Fuld, 2010, Pemetrexed in advanced non-small-cell lung cancer, Expert Opin. Pharmacother., 11, 1387, 10.1517/14656566.2010.482560 Wang, 2014, MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients, Oncol. Res. Treat., 37, 176, 10.1159/000360785 Najar, 2014, Pharmaceutical and pharmacological approaches for bioavailability enhancement of etoposide, J. Biosci., 39, 139, 10.1007/s12038-013-9399-3 Callewaert, 2012, Etoposide encapsulation in surface-modified poly(lactide-co-glycolide) nanoparticles strongly enhances glioma antitumour efficiency, J. Biomed. Mater Res. A, 101, 1319 Fatma, 2014, Novel flavonoid-based biodegradable nanoparticles for effective oral delivery of etoposide by P-glycoprotein modulation: an in vitro, ex vivo and in vivo investigations, Drug Deliv., 17, 1 Murakami, 2013, Docetaxel conjugate nanoparticles that target α-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis, Cancer Res., 72, 4862, 10.1158/0008-5472.CAN-13-0062 Mohammadi Ghalaei, 2014, Evaluating cytotoxicity of hyaluronate targeted solid lipid nanoparticles of etoposide on SK-OV-3 cells, J. Drug Deliv., 2014, 746325, 10.1155/2014/746325 Yan, 2014, Polarized immune responses modulated by layered double hydroxides nanoparticle conjugated with CpG, Biomaterials, 10.1016/j.biomaterials.2014.07.055 Kura, 2014, Toxicity and metabolism of layered double hydroxide intercalated with levodopa in a Parkinson’s disease model, Int. J. Mol. Sci., 15, 5916, 10.3390/ijms15045916 Li, 2014, Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles, Biomaterials, 35, 3331, 10.1016/j.biomaterials.2013.12.095 Chen, 2013, A facile synthesis of strong near infrared fluorescent layered double hydroxide nanovehicles with an anticancer drug for tumor optical imaging and therapy, Nanoscale, 5, 4314, 10.1039/c3nr00781b Qin, 2013, The in vitro sustained release profile and antitumor effect of etoposide-layered double hydroxide nanohybrids, Int. J. Nanomed., 8, 2053, 10.2147/IJN.S43203 Zhu, 2009, Preparation, characterization and anti-tumor property of podophyllotoxin-loaded solid lipid nanoparticles, Nanotechnology, 20, 055702, 10.1088/0957-4484/20/5/055702 Qin, 2010, The in vitro and in vivo anti-tumor effect of layered double hydroxides nanoparticles as delivery for podophyllotoxin, Int. J. Pharm., 388, 223, 10.1016/j.ijpharm.2009.12.044 Huang, 2014, Phospho-aspirin-2 (MDC-22) Inhibits estrogen receptor positive breast cancer growth both in vitro and in vivo by a redox-dependent effect, PLoS ONE, 9, e111720, 10.1371/journal.pone.0111720 Ouyang, 2006, Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model, Cancer Res., 66, 4503, 10.1158/0008-5472.CAN-05-3118 Zhu, 2012, Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles, Pharm. Res., 29, 3090, 10.1007/s11095-012-0801-x Ferreira, 2015, P-glycoprotein and membrane roles in multidrug resistance, Future Med. Chem., 7, 929, 10.4155/fmc.15.36 Chufan, 2015, Molecular basis of the polyspecificity of P-glycoprotein (ABCB1): recent biochemical and structural studies, Adv. Cancer Res., 125, 71, 10.1016/bs.acr.2014.10.003 Doss, 2013, Disruption of mitochondrial complexes in cancer stem cells through nano-based drug delivery: a promising mitochondrial medicine, Cell Biochem. Biophys., 67, 1075, 10.1007/s12013-013-9607-7 Wang, 2013, Cuprous oxide nanoparticles inhibit the growth and metastasis of melanoma by targeting mitochondria, Cell Death Dis., 4, e783, 10.1038/cddis.2013.314 Shah, 2014, Core–shell nanoparticle-based peptide therapeutics and combined hyperthermia for enhanced cancer cell apoptosis, ACS Nano, 8, 9379, 10.1021/nn503431x He, 2014, Triple-responsive expansile nanogel for tumor and mitochondria targeted photosensitizer delivery, Biomaterials, 35, 9546, 10.1016/j.biomaterials.2014.08.004 Cheng, 2012, Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death, Cancer Res., 72, 2634, 10.1158/0008-5472.CAN-11-3928 Choi, 2011, Layered double hydroxide nanoparticles as target-specific delivery carriers: uptake mechanism and toxicity, Nanomedicine, 6, 803, 10.2217/nnm.11.86 Pellegrini, 2012, SIRT3 protects from hypoxia and staurosporine-mediated cell death by maintaining mitochondrial membrane potential and intracellular pH, Cell Death Differ., 19, 1815, 10.1038/cdd.2012.62 Shalbueva, 2013, Effects of oxidative alcohol metabolism on the mitochondrial permeability transition pore and necrosis in a mouse model of alcoholic pancreatitis, Gastroenterology, 14, 437, 10.1053/j.gastro.2012.10.037 Saadati, 2014, Marked effects of combined TPGS and PVA emulsifiers in the fabrication of etoposide-loaded PLGA-PEG nanoparticles: in vitro and in vivo evaluation, Int. J. Pharm., 464, 135, 10.1016/j.ijpharm.2014.01.014 Wu, 2013, On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs, Nucleic Acids Res., 41, 10630, 10.1093/nar/gkt828 Soubeyrand, 2010, Topoisomerase IIalpha-dependent induction of a persistent DNA damage response in response to transient etoposide exposure, Mol. Oncol., 4, 38, 10.1016/j.molonc.2009.09.003 Ezoe, 2012, Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor, Int. J. Environ. Res. Public. Health, 9, 2444, 10.3390/ijerph9072444 Saifullah, 2013, Antituberculosis nanodelivery system with controlled-release properties based on para-amino salicylate-zinc aluminum-layered double-hydroxide nanocomposites, Drug Des. Devel. Ther., 7, 1365 Ali, 2011, Advances in nano drugs for cancer chemotherapy, Curr. Cancer Drug Targets, 11, 135, 10.2174/156800911794328493 Akhtar, 2013, Self-nanoemulsifying lipid carrier system for enhancement of oral bioavailability of etoposide by P-glycoprotein modulation: in vitro cell line and in vivo pharmacokinetic investigation, J. Biomed. Nanotechnol., 9, 1216, 10.1166/jbn.2013.1613 Dong, 2013, A stable and practical etoposide-containing intravenous long-/medium-chain triglycerides-based lipid emulsion formulation: pharmacokinetics, biodistribution, toxicity, and antitumor efficacy, Expert Opin. Drug Deliv., 10, 559, 10.1517/17425247.2013.769954 Bender, 2011, PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis, Oncogene, 30, 494, 10.1038/onc.2010.429 Hata, 2014, Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers, Cancer Res., 74, 3146, 10.1158/0008-5472.CAN-13-3728 Shrivastava, 2015, Anticancer effect of celastrol on human triple negative breast cancer: possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways, Exp. Mol. Pathol., 98, 313, 10.1016/j.yexmp.2015.03.031 Su, 2014, 13-acetoxysarcocrassolide induces apoptosis on human gastric carcinoma cells through mitochondria-related apoptotic pathways: p38/JNK activation and PI3K/AKT suppression, Mar. Drugs, 12, 5295, 10.3390/md12105295